Der blev udført to kontrollerede kliniske undersøgelser af Betaferon, som involverede i alt 1657 patienter med sekundær progressiv dissemineret sklerose (EDSS- basislinieværdier på 3 - 6, 5, dvs. patienter, som var i stand til at gå).
Two controlled clinical trials with Betaferon involving a total of 1657 patients with secondary progressive multiple sclerosis (baseline EDSS 3 to 6.5, i. e. patients were able to walk) were performed.